These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 9293975)

  • 1. Study of bisphosphonates leads to new views of bone remodeling, therapy for skeletal malignancy.
    Marwick C
    JAMA; 1997 Sep; 278(10):803-4. PubMed ID: 9293975
    [No Abstract]   [Full Text] [Related]  

  • 2. Skeletal Complications of Malignancy. Proceedings of a symposium. Bethesda, Maryland, April 19-20, 1997.
    Cancer; 1997 Oct; 80(8 Suppl):1527-701. PubMed ID: 9377495
    [No Abstract]   [Full Text] [Related]  

  • 3. The antitumor potential of bisphosphonates.
    Clézardin P
    Semin Oncol; 2002 Dec; 29(6 Suppl 21):33-42. PubMed ID: 12584693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The future of bisphosphonates in cancer.
    Coleman RE; Purohit OP; Vinholes JJ
    Acta Oncol; 1996; 35 Suppl 5():23-9. PubMed ID: 9142961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Managing cancer-related skeletal events with bisphosphonates.
    Rule S
    Hosp Med; 2004 Jun; 65(6):355-60. PubMed ID: 15222212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical pharmacology of zoledronic acid.
    Green JR
    Semin Oncol; 2002 Dec; 29(6 Suppl 21):3-11. PubMed ID: 12584689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone turnover markers as predictive indicators of outcome in patients with breast cancer and bone metastases treated with bisphosphonates: results from a 2-year multicentre observational study (ZOMAR study).
    Barnadas A; Manso L; de la Piedra C; Meseguer C; Crespo C; Gómez P; Calvo L; Martinez P; Ruiz-Borrego M; Perelló A; Antón A; Codes M; Margelí M; Murias A; Salvador J; Seguí MÁ; de Juan A; Gavilá J; Luque M; Pérez D; Zamora P; Arizcuma A; Chacón JI; Heras L; Martin-Fernández M; Mahillo-Fernández I; Tusquets I
    Bone; 2014 Nov; 68():32-40. PubMed ID: 25108081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonates in breast cancer patients with skeletal metastases.
    Shapiro CL
    Hematol Oncol Clin North Am; 1994 Feb; 8(1):153-63. PubMed ID: 8150777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of bisphosphonates in the management of bone metastases in prostate cancer.
    Saad F; Chi K; Fleshner N
    Can J Urol; 2004 Oct; 11(5):2376-82. PubMed ID: 15576002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Bisphosphonates and bone metastases of solid tumors: therapeutic interest despite its anti-resorptive properties].
    Clézardin P
    Prog Urol; 2003 Apr; 13(2 Suppl 1):28-35. PubMed ID: 12815807
    [No Abstract]   [Full Text] [Related]  

  • 11. [The application advances of bisphosphonates in bone metastasis].
    Liang P
    Zhongguo Gu Shang; 2008 Jun; 21(6):480-2. PubMed ID: 19108448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonates: expanded roles in the treatment of patients with cancer.
    Viale PH; Sanchez Yamamoto D
    Clin J Oncol Nurs; 2003; 7(4):393-401. PubMed ID: 12929272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bisphosphonates for the prevention of bone metastases.
    Coleman RE
    Semin Oncol; 2002 Dec; 29(6 Suppl 21):43-9. PubMed ID: 12584694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The role of bisphosphonates in the treatment of bone metastases from urogenital cancer ].
    Colombel M
    Prog Urol; 2003 Apr; 13(2 Suppl 1):18-23. PubMed ID: 12815805
    [No Abstract]   [Full Text] [Related]  

  • 15. Use of bisphosphonates in patients with metastatic bone disease.
    Berenson JR; Lipton A
    Oncology (Williston Park); 1998 Nov; 12(11):1573-9; discussion 1579-81. PubMed ID: 9834935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonates for treatment and prevention of bone metastases.
    Michaelson MD; Smith MR
    J Clin Oncol; 2005 Nov; 23(32):8219-24. PubMed ID: 16278476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Bisphosphonates in the therapy of cancer patients].
    Jantunen E; Kumpulainen E
    Duodecim; 1999; 115(1):27-32. PubMed ID: 11830857
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid.
    Pectasides D; Nikolaou M; Farmakis D; Kanakis I; Gaglia A; Kountourakis P; Karamanos NK; Economopoulos T; Raptis SA
    Anticancer Res; 2005; 25(2B):1457-63. PubMed ID: 15865105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bone targeting agents: bisphosphonates].
    Debiais F
    Bull Cancer; 2013 Nov; 100(11):1199-206. PubMed ID: 24158668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of bone metastases with bisphosphonates].
    Gremaud M; Delouche D; Monnerat C
    Rev Med Suisse; 2006 Aug; 2(75):1861-6. PubMed ID: 16948423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.